Legato Capital Management’s TG Therapeutics TGTX Stock Holding History

Legato Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$793K	Hold	14,437	–	–	0.07%	418
2026 Q1	$480K	Buy	+14,437	New	+$430K	0.04%	543
2025 Q3	–	Sell	-19,529	Closed	-$703K	–	624
2025 Q2	$703K	Buy	19,529 +5,407	+38%	+$201K	0.08%	371
2025 Q1	$557K	Buy	14,122 +3,775	+36%	+$127K	0.08%	406
2024 Q4	$311K	Sell	10,347 -3,104	-23%	-$89.1K	0.04%	492
2024 Q3	$315K	Buy	+13,451	New	+$294K	0.04%	506
2023 Q3	–	Sell	-10,710	Closed	-$266K	–	642
2023 Q2	$266K	Buy	+10,710	New	+$277K	0.04%	491
2021 Q3	–	Sell	-19,348	Closed	-$751K	–	308
2021 Q2	$751K	Buy	+19,348	New	+$760K	0.11%	199

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Legato Capital Management's TGTX Position: Q2 2026 in Review

Legato Capital Management held its TG Therapeutics (TGTX) position steady in Q2 2026 at 14,437 shares worth $793K. The position accounts for 0.07% of the portfolio, ranked #418.

Legato Capital Management first reported a position in TGTX in Q2 2021 and has held it in 8 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Legato Capital Management held 14,437 shares of TG Therapeutics worth $793K as of Q2 2026.
Legato Capital Management left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up 0.07% of Legato Capital Management's portfolio in Q2 2026, its #418 holding.
Legato Capital Management first reported a position in TG Therapeutics in Q2 2021 and has held it in 8 quarters since.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.